DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) provides LAMA/LABA therapy.
David Frabotta
Advertisement
Articles by David Frabotta
Approved regulations allow for some flexibility for drugs that can be redistributed or qualify for manufacturer credit.
Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.
Health systems employ Artifical Intelligence and integrated medication management to address diversion.
Advertisement
Latest Updated Articles
BD Unveils New Tool to Fight Opioid CrisisDecember 17th 2018
Balversa Fast-Tracked for Bladder CancerApril 12th 2019
EPA’s New Rules on Drug Disposal Begin in AugustApril 17th 2019
FDA Approves New COPD Maintenance TreatmentApril 24th 2019
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
Study Links Live Flu Vaccine With Rise in Pneumococcal Disease
4
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
5